Table 2.
Pathway |
UC patients |
Healthy partners |
P value | ||
Mean abundance | Standard error | Mean abundance | Standard error | ||
Membrane transport | |||||
ABC transporters1 | 3.0271 | 0.5695 | 3.7117 | 0.7130 | 0.04149 |
Signal transduction | |||||
Phosphatidylinositol signaling system | 0.1022 | 0.0155 | 0.0845 | 0.0182 | 0.018959 |
Signaling molecules and interaction | |||||
G protein-coupled receptors1 | 1.76 × 10-5 | 3.63 × 10-5 | 6.54 × 10-5 | 1.02 × 10-5 | 0.02515 |
Infectious diseases | |||||
Staphylococcus aureus infection | 0.295 | 0.582 | 0.00545 | 0.00442 | 0.041492 |
Biosynthesis of other secondary | |||||
Metabolites; isoflavonoid biosynthesis | 8.97 × 10-6 | 8.03 × 10-6 | 9.75 × 10-7 | 1.39 × 10-7 | 0.003511 |
Novobiocin biosynthesis1 | 0.1161 | 0.010 | 0.1277 | 0.0122 | 0.02494 |
Carbohydrate metabolism | |||||
C5-Branched dibasic acid metabolism1 | 0.287 | 0.0536 | 0.3214 | 0.0218 | 0.04149 |
Glycan biosynthesis and metabolism | |||||
Glycosphingolipid biosynthesis | 3.74 × 10-4 | 3.95 × 10-4 | 1.37 × 10-4 | 1.91× 10-4 | 0.032476 |
Lipid metabolism | |||||
Linoleic acid metabolism | 0.0851 | 0.0505 | 0.0518 | 0.0197 | 0.024942 |
Primary bile acid biosynthesis | 0.0416 | 0.0186 | 0.0257 | 0.0120 | 0.018959 |
Secondary bile acid biosynthesis | 0.0414 | 0.0187 | 0.0255 | 0.0120 | 0.018959 |
Metabolism of cofactors and vitamins | |||||
Porphyrin and chlorophy II metabolism1 | 0.7225 | 0.1723 | 0.8785 | 0.1079 | 0.03248 |
Nucleotide metabolism | |||||
Purine metabolism | 2.2171 | 0.2176 | 2.0283 | 0.1561 | 0.018959 |
Xenobiotics biodegradation and metabolism | |||||
Atrazine degradation1 | 0.0227 | 0.0252 | 0.0441 | 0.0329 | 0.03248 |
Ethylbenzene degradation | 0.0769 | 0.0643 | 0.0429 | 0.00795 | 0.018959 |
Naphthalene degradation | 0.1827 | 0.0823 | 0.1300 | 0.0261 | 0.018959 |
Nitrotoluene degradation1 | 0.0651 | 0.0346 | 0.1022 | 0.0198 | 0.02494 |
Styrene degradation1 | 0.0155 | 0.0131 | 0.0329 | 0.0231 | 0.02494 |
Indicated higher abundance in the healthy partners (P < 0.05). UC: Ulcerative colitis.